Elevance Health, Inc. 8-K

What Happened

• Elevance Health, Inc. filed a Form 8-K on March 10, 2026 saying company officers will speak with investors and analysts and will reaffirm their full-year 2026 guidance: adjusted shareholders’ earnings of at least $25.50 per diluted share and a 2026 benefit expense ratio of 90.2% ± 50 basis points.
• The company reiterated that on February 27, 2026 CMS notified Elevance of its intent to impose intermediate sanctions — including suspension of Medicare Advantage enrollment and certain beneficiary communications — effective March 31, 2026 unless CMS determines issues are satisfactorily addressed. The company’s guidance “includes the impact of the Sanctions, if imposed.”
• Elevance said it cannot reasonably provide a GAAP reconciliation from the adjusted shareholders’ earnings guidance to GAAP shareholders’ earnings per diluted share for full-year 2026 without unreasonable effort, because it cannot estimate potential financial payments to resolve the CMS matter.

Key Details

• Reaffirmed guidance: adjusted shareholders’ earnings ≥ $25.50 per diluted share for FY2026.
• Reaffirmed benefit expense ratio guidance: 90.2% ± 50 basis points for 2026.
• CMS notice date: February 27, 2026; potential sanctions effective March 31, 2026 (suspending MA enrollment and certain communications).
• Form 8-K filed March 10, 2026; prior related disclosure filed March 2, 2026.

Why It Matters

• Investors get a clear signal that management expects to meet its adjusted earnings and expense targets for 2026 despite the regulatory notice from CMS. The guidance explicitly accounts for the potential sanctions scenario.
• The CMS action, if imposed, could limit membership growth and marketing/communication activities in Medicare Advantage plans, which are material to revenue and future enrollment trends. That risk is ongoing and could involve financial payments or remediation.
• Management’s inability to reconcile adjusted guidance to GAAP earnings for 2026 means there is uncertainty about the GAAP impact of the CMS matter until outcomes (and any payments or remedies) are known. This reduces near-term transparency around GAAP EPS.